PDCD1 and melanoma: Similarly, lenvatinib or anti-PD-1 alone significantly delayed tumor growth compared with vehicle treatment in the B16-F10 mouse melanoma syngeneic model, and lenvatinib plus anti-PD-1 combination therapy was more potent than either treatment alone (S6 Fig).